Nivolumab, the first human IgG4 monoclonal antibody against PD-1, was approved by the FDA for various indications, including metastatic melanoma, non-small-cell lung cancer, and Hodgkin’s lymphoma [3,4,5,6]. Here, PDCD1 is linked to metastatic melanoma.